Health services company Progressive Care (OTC PINK:RXMD) stated on Thursday that it has recorded nearly 180,000 prescriptions in 2015 through its subsidiary PharmCo.
This marks an improvement of 28% in prescriptions over last year, according to the company.
In 2015, the company collected over USD13.5m in net pharmacy revenues, which reflects a growth of about 24% when compared to 2014.
During the final month and quarter, the company announced revenue growth of over 61% and 35%, respectively, when compared to the same time periods last year. The compounded medication division, the new additions in the marketing team, the expanded marketing campaigns and the large clinics and physicians networks is the primary driver of revenue growth.
For the Q4, the company reported over 48,000 in prescriptions resulting in record revenues at USD3.9m.
Additionally, December marked the strongest month since the company's inception with over USD1.4m in net pharmacy revenues.
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline